Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Long-Term Investments (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Long-Term Investments for 10 consecutive years, with $22.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments changed N/A to $22.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.1 million, a N/A change, with the full-year FY2024 number at $135.0 million, up 4113.48% from a year prior.
  • Long-Term Investments was $22.1 million for Q3 2025 at Ultragenyx Pharmaceutical, down from $51.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $215.5 million in Q1 2022 to a low of $2.8 million in Q4 2022.
  • A 5-year average of $82.1 million and a median of $75.1 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: tumbled 88.04% in 2021, then soared 4113.48% in 2024.
  • Ultragenyx Pharmaceutical's Long-Term Investments stood at $18.5 million in 2021, then plummeted by 84.83% to $2.8 million in 2022, then increased by 14.14% to $3.2 million in 2023, then skyrocketed by 4113.48% to $135.0 million in 2024, then tumbled by 83.65% to $22.1 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Long-Term Investments are $22.1 million (Q3 2025), $51.5 million (Q2 2025), and $68.6 million (Q1 2025).